| 000 | 01787 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513120446.0 | ||
| 264 | 0 | _c19970611 | |
| 008 | 199706s 0 0 eng d | ||
| 022 | _a0937-941X | ||
| 024 | 7 |
_a10.1007/BF01623688 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZamberlan, N | |
| 245 | 0 | 0 |
_aIntermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist. _h[electronic resource] |
| 260 |
_bOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA _c1997 |
||
| 300 |
_a133-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnthropometry |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aCalcium _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEtidronic Acid _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHirsutism _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLuteolytic Agents _xadverse effects |
| 650 | 0 | 4 |
_aOsteoporosis _xchemically induced |
| 650 | 0 | 4 |
_aPolycystic Ovary Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aTriptorelin Pamoate _xadverse effects |
| 700 | 1 | _aCastello, R | |
| 700 | 1 | _aGatti, D | |
| 700 | 1 | _aRossini, M | |
| 700 | 1 | _aBraga, V | |
| 700 | 1 | _aFracassi, E | |
| 700 | 1 | _aAdami, S | |
| 773 | 0 |
_tOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA _gvol. 7 _gno. 2 _gp. 133-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF01623688 _zAvailable from publisher's website |
| 999 |
_c9147534 _d9147534 |
||